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given the increase in medicines, especially injectables, coming to market in the 
future.  
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OBJECTIVES: Pharmacoeconomic models in diabetes link blood glucose control 
as measured by hemoglobin A1c to diabetes-related complications. Despite 
advances in diabetes modeling, there is limited research on the relationship 
between A1c and health-related quality of life (HRQoL) that is independent of 
diabetes-related complications. Our objective was to quantify the cross-sectional 
relationship between A1c and HRQoL utility scores in adult type-1 diabetes (T1D) 
patients, after adjusting for diabetes-related complications. METHODS: The 
EuroQoL-5 dimensions (EQ-5D) questionnaire was administered to adult T1D 
patients during one clinic visit at the University of Colorado Barbara Davis 
Center for Diabetes (BDC) from November 2011 – July 2012. We combined 
individual-level data from the EQ-5D questionnaire with A1c data from the BDC 
medical record. Utility scores were derived using the US time-tradeoff valuation 
of the EQ-5D. Unadjusted mean utility scores were estimated for the overall 
population and stratified by A1c. We used ordinary least squares regression with 
robust standard errors to estimate the cross-sectional relationship between A1c 
and utility, adjusting for demographic variables and diabetes-related 
complications. RESULTS: Mean (SD) age in years for the population (N = 176) was 
38 (12.2); duration of diabetes in years was 22 (12.1); and number of chronic 
conditions other than diabetes was 2.7 (2.0). Unadjusted mean (SD) utility was 
0.94 (0.09) for those with A1c levels < 7% (n = 54); 0.89 (0.15) for those with A1c ≥ 
7% (n = 122); and 0.91 (0.14) for all patients. On average, a 1% absolute increase in 
A1c was associated with a significant disutility of -0.03 (95% CI: -0.06, -0.006), 
after adjustment. CONCLUSIONS: Findings suggest that after adjusting for 
diabetes-related complications, poor blood glucose control is associated with 
decrements in utility not currently captured in existing diabetes 
pharmacoeconomic models. Longitudinal research is needed to strengthen this 
cross-sectional evidence on the relationship between A1c and HRQoL utility.  
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OBJECTIVES: Generic health measures are routinely used to assess HRQoL in 
population studies of persons with diabetes and other chronic illness. It is not 
known whether these measures provide consistent results in assessing HRQoL in 
patients with diabetes or whether these measures are able to discriminate 
between the HRQoL of persons with and without diabetes and across levels of 
diabetes severity. To compare HRQoL differences across levels of diabetes 
severity using six generic indexes and to examine the generic indexes ability to 
discriminate between the HRQoL levels across diabetes severity. METHODS: The 
National Health Measurement Study is a population-based, cross-sectional 
survey of 3844 non-institutionalized adults in the United States. Participants 
completed six generic measures of HRQoL—EQ-5D, HUI2, HUI3, QWB-SA, SF-36v2 
(yielding PCS, MCS, and SF-6D), and HALex. Diabetes severity was classified as 
non-diabetic, diabetes without medication, diabetes with medication, and 
diabetes with insulin. Weighted mean difference scores between each diabetes 
category adjusted for age, sex, and gender were calculated for each index. Effect 
sizes were calculated for each index between each diabetes group by 
standardizing to the population standard deviation among those without 
diabetes. RESULTS: A total of 726 (19%, unweighted) individuals self-reported 
diabetes. Across all indexes persons with diabetes demonstrated statistically 
significantly lower unadjusted and adjusted HRQoL scores than those without 
diabetes (p < 0.001). The HALex had the highest effect sizes for all comparisons 
between diabetes categories (ranging from 0.16 through 1.30), followed by the SF-
36v2 PCS (ranging from 0.24 through 0.98), and the SF-36v2 MCS (ranging from 
0.06 through 0.57). CONCLUSIONS: Results demonstrate the ability for generic 
HRQoL indexes to differentiate between persons with and without self-reported 
diabetes. The HALex was consistently better at differentiating among diabetes 
severity as. This study indicates that generic indexes are useful for evaluating 
HRQoL even in a diabetes-specific context.  
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OBJECTIVES: Islet transplantation is an accepted transplantation method in type 
I Diabetes Mellitus, yet islet survival is hampered due to an insufficient 
transplantation site and severe immunological and inflammatory responses. The 
development of a bio-artificial pancreas (BAP) may contribute to transplanted 
islet functionality and survival. The objective of this study is to identify the most 
important transplantation characteristics and to asses patients’ and 
endocrinologists´ preferences for three potential BAP scenarios in order to guide 
further development. METHODS: The current standard of care and 
characteristics that determine clinical decisions for a particular transplantation 
method were analysed based on a literature search, semi-structured interviews 
and focus groups. A decision tree was constructed covering the main attributes 
effectiveness, patient safety, impact of the treatment for the patient and the 
required amount of donor material. The analytic hierarchy process was used to 
obtain the relative weights for each defined attribute in type I DM patients (n=21) 
and endocrinologists (n=12). Based on these weights, overall preferences for 
three potential BAP scenarios were calculated and compared to conventional 
pancreas and islets transplantation. RESULTS: The three most important 
treatment attributes are the effectiveness of the transplant for glucose control, 
patient safety and the surgical procedure. However, there were considerable 
differences between patients and endocrinologists in the importance of 
effectiveness of the transplant (weights were 0.471 and 0.257 respectively) and 
patient safety (0.331 and 0.423). While considering both endocrinologists’ and 
patients’ preferences, all three BAP scenarios assessed gained a higher overall 
preference in comparison to conventional islet transplantation. CONCLUSIONS: 
This study indicates the prospects of BAP development. Nevertheless, the study 
also highlights the discrepancies between endocrinologists’ and type 1 diabetes 
patients’ preferences. In the future, BAP developers can benefit from this 
multidisciplinary approach by critically reviewing their BAP design, in view of 
patient safety and clinical performance.  
 
PDB74  
PATIENT PREFERENCES FOR THE TREATMENT OF TYPE-2 DIABETES:  
A SCOPING REVIEW AND ASSESSMENT OF METHODS  
Joy SM1, Purnell TS2, Little E3, Bridges JF1 
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins Medical 
Institutions, Baltimore, MD, USA, 3Johns Hopkins University, Baltimore, MD, USA  
OBJECTIVES: Patient-centered outcomes research (PCOR) aims to incorporate 
patient preference into the evaluation of competing therapies. We sought to 
identify and categorize methods used to assess patient preferences in the 
literature, focusing on medication preference of adults with type-2 diabetes. 
METHODS: Studies of patient preferences for type-2 diabetes medications were 
identified from the PubMed, EMBASE, CINAHL and EconLit databases using a 
registered study protocol (CRD42012002285) and aided by the PRISMA guidelines. 
Studies were included if they presented data on the preferences of adults with 
type-2 diabetes and excluded if they had no primary data on preference, focused 
only on behavioral change or on treatments for complications or co-morbid 
conditions. Two investigators reviewed titles, abstracts, and articles sequentially 
to select studies based on the inclusion and exclusion criteria. Disagreements 
were resolved by consensus. Data were abstracted into standardized forms and 
summary statistics were calculated. RESULTS: In total, 1883 unique papers were 
identified, of which 57 published between 1985 and 2011 met the selection 
criteria. Of these, 40% could be categorized as being primarily focused on 
preferences, using systematic methods such as conjoint analysis (n=10), 
contingent valuation (n=1), qualitative research (n=1), revealed preference (n=5), 
standard gamble (n=2), and time trade-off (n=6). The remaining 35 papers had 
preference data as a secondary aim, asking patients about their preferences 
and/or willingness to continue using or recommend products studied in a 
clinical trial. CONCLUSIONS: While an extensive literature focused on 
medication preferences of patients with type-2 diabetes can be identified, 
evidence synthesis is hindered by the diverse range of methods, including a 
majority of papers that assess preferences in an unsystematic way. Further 
research is needed to compare results of different methods and to assess the 
quality of preference studies.  
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OBJECTIVES: Severe hypoglycemic events are serious yet underreported 
condition that may lead to morbidity and even mortality. These events are an 
important limiting factor to good glycemic control. The objective of this study 
was to determine self-reported severe hypoglycemic rate in T2DM, basal insulin 
users in the National Health and Wellness Survey (NHWS) US population. 
METHODS: NHWS is a large international self-reported, real-world, patient-level 
survey which collects information on metrics such as patients’ demographics, 
behaviors and attitudes towards diseases in over 165 therapeutic conditions. We 
used an extract from the 2010 NHWS dataset composed of T2DM patients who 
were taking basal insulin monotherapy or in combination with oral anti-diabetic 
medications (OAD). The respondents (n=425) recalled number of severe 
hypoglycemic events they had in the last 4 weeks and 6 months prior to the 
survey. We analyzed event rates using multiple regression. RESULTS: Fifty-one 
percent of respondents were female and the mean age was 61.6 (SD=10.03). The 
overall severe hypoglycemia event rate for the 4 week and 6 month recall periods 
were 0.34 and 0.27 per patient-year, respectively. Among basal insulin only users 
(n=60), the event rates were 0.43 (6 month recall) and 0.37 (4 week recall) per 
patient-year. Among basal insulin plus OAD users (n=365), the rates were 0.32 (6 
month recall) and 0.26 (4 week recall) per patient-year. The relationship between 
presence of severe hypoglycemia rates and insulin treatment categories after 
adjusting for the covariates were non-significant. CONCLUSIONS: Basal insulin 
only users reported higher rates of severe hypoglycemia than basal insulin plus 
OAD users, but the difference was not statistically significant likely due to small 
sample size. Recall bias could also contribute to differences between the rates. 
Overall, our rates were higher than what have been reported in the literature 
with claims data, suggesting that severe hypoglycemia may be underreported.  
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